Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Metabolic syndrome and endocrine status in HIV-infected transwomen.

Pommier JD, Laouénan C, Michard F, Papot E, Urios P, Boutten A, Peytavin G, Ghander C, Lariven S, Castanedo G, Moho D, Landman R, Phung B, Perez E, Julia Z, Descamps D, Roland-Nicaise P, Le Gac S, Yazdanpanah Y, Guibourdenche J, Yeni P.

AIDS. 2019 Apr 1;33(5):855-865. doi: 10.1097/QAD.0000000000002152.

PMID:
30664006
2.

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).

Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y; LAMIDOL Study Group.

J Antimicrob Chemother. 2019 Mar 1;74(3):739-745. doi: 10.1093/jac/dky467.

PMID:
30476165
3.

Contribution of brain imaging to the diagnosis of intracranial tuberculoma and other brain lesions in patients presenting with miliary tuberculosis.

Bleibtreu A, Grall N, Laissy JP, Rioux C, Strukov A, Lariven S, Yeni P, Yazdanpanah Y, Joly V.

Med Mal Infect. 2018 Dec;48(8):533-539. doi: 10.1016/j.medmal.2018.06.006. Epub 2018 Jul 13.

PMID:
30017477
4.

Assessement of Awareness of, Concerns and Attitudes Towards HIV-Related Court-Case Sentences in France in a Representative Sample of People Living with HIV (ANRS VESPA2 Survey).

Suzan-Monti M, Celse M, Vilotitch A, Demoulin B, Dray-Spira R, Yéni P, Lert F, Spire B; ANRS VESPA2 study group.

AIDS Behav. 2018 Oct;22(10):3264-3272. doi: 10.1007/s10461-018-2077-6.

PMID:
29512033
5.

Budget impact of antiretroviral therapy in a French clinic cohort.

Papot E, Landman R, Louni F, Charpentier C, Peytavin G, Certain A, Fradet C, Castro DR, Preau M, Goujard C, Yeni P, Yazdanpanah Y; ANRS-GOTA Study Group.

AIDS. 2017 Jun 1;31(9):1271-1279. doi: 10.1097/QAD.0000000000001467.

PMID:
28323753
6.

Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.

Madelain V, Le MP, Champenois K, Charpentier C, Landman R, Joly V, Yeni P, Descamps D, Yazdanpanah Y, Peytavin G.

J Antimicrob Chemother. 2017 Apr 1;72(4):1137-1146. doi: 10.1093/jac/dkw527.

7.

Abacavir has no prothrombotic effect on platelets in vitro.

Diallo YL, Ollivier V, Joly V, Faille D, Catalano G, Jandrot-Perrus M, Rauch A, Yeni P, Ajzenberg N.

J Antimicrob Chemother. 2016 Dec;71(12):3506-3509. Epub 2016 Aug 11.

PMID:
27516475
8.

Epidemiological Profile of Newly Diagnosed HIV-Infected Patients in Northern Paris: A Retrospective Study.

Senard O, Burdet C, Visseaux B, Charpentier C, Le Gac S, Julia Z, Lariven S, Descamps D, Yazdanpanah Y, Yeni P, Joly V.

AIDS Res Hum Retroviruses. 2017 Jan;33(1):11-16. doi: 10.1089/AID.2016.0036. Epub 2016 Sep 7.

PMID:
27476681
9.

Determinants of macroscopic anal cancer and precancerous lesions in 1206 HIV-infected screened patients.

Abramowitz L, Benabderrahmane D, Walker F, Yazdapanah Y, Yéni P, Rioux C, Bouscarat F, Lafferre E, Mentré F, Duval X.

Colorectal Dis. 2016 Oct;18(10):997-1004. doi: 10.1111/codi.13304.

PMID:
26896041
10.

Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial).

Piroth L, Moinot L, Yeni P, Avettand-Fénoel V, Reynes J, Girard PM, Marchou B, Georget A, Rouzioux C, Autran B, Duvillard L, Chêne G, Fagard C; ANRS 141 TIPI Trial Study Group.

J Antimicrob Chemother. 2016 Feb;71(2):490-6. doi: 10.1093/jac/dkv369. Epub 2015 Nov 14.

PMID:
26568566
11.

Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.

Charpentier C, Lê MP, Joly V, Visseaux B, Lariven S, Phung B, Yéni P, Yazdanpanah Y, Descamps D, Peytavin G, Landman R.

PLoS One. 2015 Jul 30;10(7):e0134430. doi: 10.1371/journal.pone.0134430. eCollection 2015.

12.

Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients.

Pommier JD, Ben Lasfar N, Van Grunderbeeck N, Burdet C, Laouénan C, Rioux C, Pierre-Audigier C, Meybeck A, Choudat L, Benchikh A, Nguyen S, Bouvet E, Yeni P, Yazdanpanah Y, Joly V.

Infect Dis (Lond). 2015;47(10):725-31. doi: 10.3109/23744235.2015.1055794. Epub 2015 Jun 16.

PMID:
26077036
13.

Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.

Brunetta J, Moreno Guillén S, Antinori A, Yeni P, Wade B, Johnson M, Shalit P, Ebrahimi R, Johnson B, Walker I, De-Oertel S.

Patient. 2015 Jun;8(3):257-67. doi: 10.1007/s40271-015-0123-2.

14.

Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.

Chéret A, Nembot G, Mélard A, Lascoux C, Slama L, Miailhes P, Yeni P, Abel S, Avettand-Fenoel V, Venet A, Chaix ML, Molina JM, Katlama C, Goujard C, Tamalet C, Raffi F, Lafeuillade A, Reynes J, Ravaux I, Hoën B, Delfraissy JF, Meyer L, Rouzioux C; OPTIPRIM ANRS Study Group.

Lancet Infect Dis. 2015 Apr;15(4):387-96. doi: 10.1016/S1473-3099(15)70021-6. Epub 2015 Feb 18.

PMID:
25701561
15.

[An update on measles].

Caseris M, Burdet C, Lepeule R, Houhou N, Yeni P, Yazdanpanah Y, Joly V.

Rev Med Interne. 2015 May;36(5):339-45. doi: 10.1016/j.revmed.2014.10.362. Epub 2015 Jan 8. Review. French.

PMID:
25579464
16.

Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART.

El Khoury P, Ghislain M, Villard EF, Le Goff W, Lascoux-Combe C, Yeni P, Meyer L, Vigouroux C, Goujard C, Guerin M.

J Lipid Res. 2015 Mar;56(3):692-702. doi: 10.1194/jlr.M054510. Epub 2015 Jan 8.

17.

[HIV infection and social condition: a disease which remains singular].

Celse M, Geffroy L, Yeni P.

Rev Prat. 2014 Oct;64(8):1099-102. French.

PMID:
25510134
18.

[HIV infection. Screening, broadcast treatment and prevention of infection are now linked ].

Yeni P.

Rev Prat. 2014 Oct;64(8):1057-9. French. No abstract available.

PMID:
25510125
19.

Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.

Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Yeni P, Strohmaier KM, Rodgers AJ, Barnard RJ, Nguyen BY, Teppler H; BENCHMRK Study Teams.

Antivir Ther. 2015;20(3):307-15. doi: 10.3851/IMP2912. Epub 2014 Oct 27.

20.

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.

Charpentier C, Choquet M, Joly V, Yeni P, Visseaux B, Caseris M, Brun-Vézinet F, Yazdanpanah Y, Peytavin G, Descamps D, Landman R.

J Antimicrob Chemother. 2014 Oct;69(10):2819-25. doi: 10.1093/jac/dku211. Epub 2014 Jun 19.

PMID:
24948705
21.

Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen.

Charpentier C, Joly V, Ghosn J, Yeni P, Raffi F, Descamps D, Morand-Joubert L.

J Antimicrob Chemother. 2014 Sep;69(9):2588-90. doi: 10.1093/jac/dku155. Epub 2014 May 9. No abstract available.

PMID:
24816213
22.

French 2010-2011 measles outbreak in adults: report from a Parisian teaching hospital.

Caseris M, Houhou N, Longuet P, Rioux C, Lepeule R, Choquet C, Yazdanpanah Y, Yeni P, Joly V.

Clin Microbiol Infect. 2014 Apr;20(4):O242-4. doi: 10.1111/1469-0691.12384. Epub 2013 Oct 30.

23.

Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO).

Wohl DA, Orkin C, Doroana M, Pilotto JH, Sungkanuparph S, Yeni P, Vanveggel S, Deckx H, Boven K.

Antivir Ther. 2014;19(2):191-200. doi: 10.3851/IMP2721. Epub 2014 Jan 16.

PMID:
24430534
24.

Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.

Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts.

PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Print 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/aed12a66-9c76-4e49-806b-881a2fe23bba. Goujard, Cecile [added].

25.

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.

Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Strohmaier KM, Wan H, Barnard RJ, Nguyen BY, Teppler H; BENCHMRK Study Teams.

Lancet Infect Dis. 2013 Jul;13(7):587-96. doi: 10.1016/S1473-3099(13)70093-8. Epub 2013 May 7.

26.

Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).

Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P; S 130 Apollo Trial Group.

Antimicrob Agents Chemother. 2013 Feb;57(2):758-65. doi: 10.1128/AAC.01662-12. Epub 2012 Nov 19.

27.

Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.

Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, de Verdière NC, Raffi F, Yeni P, Descamps D; ANRS 130 APOLLO Trial Study Group.

J Antimicrob Chemother. 2013 Mar;68(3):690-6. doi: 10.1093/jac/dks455. Epub 2012 Nov 14.

PMID:
23152480
28.

Acute lung, heart, liver, and pancreatic involvements with hyponatremia and retinochoroiditis in a 33-year-old French Guianan patient.

Groh M, Faussart A, Villena I, Ajzenberg D, Carme B, Demar M, Joly V, Houze S, Simon S, Aubert D, Charlois-Ou C, Yeni P.

PLoS Negl Trop Dis. 2012;6(10):e1802. doi: 10.1371/journal.pntd.0001802. Epub 2012 Oct 25. No abstract available.

29.

Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.

Lê MP, Solas C, Garraffo R, Gagnieu MC, Muret P, Yeni P, Dhiver C, Katlama C, Poizot-Martin I, Durant J, Peytavin G.

J Antimicrob Chemother. 2012 Nov;67(11):2779-81. doi: 10.1093/jac/dks260. Epub 2012 Jul 6. No abstract available.

PMID:
22773742
30.

Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.

Charpentier C, Landman R, Laouénan C, Joly V, Hamet G, Damond F, Brun-Vézinet F, Mentré F, Descamps D, Yeni P.

J Antimicrob Chemother. 2012 Sep;67(9):2231-5. doi: 10.1093/jac/dks191. Epub 2012 May 29.

PMID:
22643190
31.

What is a modest public health impact?

Yazdanpanah Y, Walensky RP, Rozenbaum W, Yeni P, Paltiel AD.

Arch Intern Med. 2012 Mar 26;172(6):521-2; author reply 522-3. doi: 10.1001/archinternmed.2011.1876. No abstract available.

PMID:
22450944
32.

Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.

Charpentier C, Larrouy L, Visseaux B, Landman R, Levittas M, Storto A, Damond F, Yazdanpanah Y, Yeni P, Brun-Vézinet F, Descamps D.

J Antimicrob Chemother. 2012 Jun;67(6):1459-61. doi: 10.1093/jac/dks067. Epub 2012 Mar 1.

PMID:
22382470
33.

Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.

Marcelin AG, Charpentier C, Wirden M, Landman R, Valantin MA, Simon A, Katlama C, Yeni P, Descamps D, Aubron-Olivier C, Calvez V.

J Antimicrob Chemother. 2012 Jun;67(6):1475-8. doi: 10.1093/jac/dks047. Epub 2012 Feb 26.

PMID:
22371439
34.

Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.

Fagard C, Colin C, Charpentier C, Rami A, Jacomet C, Yeni P, Vittecoq D, Katlama C, Molina JM, Descamps D, Chêne G, Yazdanpanah Y; ANRS 139 TRIO Trial Group.

J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):489-93. doi: 10.1097/QAI.0b013e31824bb720.

PMID:
22293546
35.

Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort.

Boufassa F, Goujard C, Viard JP, Carlier R, Lefebvre B, Yeni P, Bouchaud O, Capeau J, Meyer L, Vigouroux C; ANRS COPANA Cohort Study Group.

Antivir Ther. 2012;17(1):91-100. doi: 10.3851/IMP1916.

36.

Suitability of initial antibiotic therapy for the treatment of bloodstream infections and the potential role of antibiotic management teams in improving it.

Diamantis S, Rioux C, Bonnal C, Farfour É, Papy E, Andremont A, Yeni P, Bouvet É, Lucet JC.

Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1667-71. doi: 10.1007/s10096-011-1491-8. Epub 2011 Dec 2.

PMID:
22134774
37.

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, Rockstroh JK, Almond S, Song I, Brothers C, Min S.

Lancet Infect Dis. 2012 Feb;12(2):111-8. doi: 10.1016/S1473-3099(11)70290-0. Epub 2011 Oct 20.

PMID:
22018760
38.

Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity.

Battivelli E, Migraine J, Lecossier D, Yeni P, Clavel F, Hance AJ.

J Virol. 2011 Nov;85(22):11846-54. doi: 10.1128/JVI.05201-11. Epub 2011 Sep 14.

39.

Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.

Larrouy L, Charpentier C, Landman R, Capitant C, Chazallon C, Yeni P, Peytavin G, Damond F, Brun-Vezinet F, Descamps D; ANRS 127 study group.

AIDS. 2011 Nov 13;25(17):2143-8. doi: 10.1097/QAD.0b013e32834cabb9.

PMID:
21904187
40.

Impact of adding enfuvirtide to the predictive value of the darunavir genotypic resistance score.

Charpentier C, Lambert-Niclot S, Larrouy L, Peytavin G, Valantin MA, Landman R, Katlama C, Yeni P, Felices M, Brun-Vézinet F, Calvez V, Marcelin AG, Descamps D.

J Acquir Immune Defic Syndr. 2011 May 1;57(1):e15-7. doi: 10.1097/QAI.0b013e3182139755. No abstract available.

PMID:
21734472
41.

Darunavir: an effective protease inhibitor for HIV-infected patients.

Phung BC, Yeni P.

Expert Rev Anti Infect Ther. 2011 Jun;9(6):631-43. doi: 10.1586/eri.11.48. Review.

PMID:
21692667
42.

Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial).

Feeney ER, Chazallon C, O'Brien N, Meiffrédy V, Goodall RL, Aboulker JP, Cooper DA, Yeni P, Mallon PW; INITIO Trial International Co-ordinating Committee.

HIV Med. 2011 Nov;12(10):602-9. doi: 10.1111/j.1468-1293.2011.00934.x. Epub 2011 May 22.

43.

Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.

Larrouy L, Lambert-Niclot S, Charpentier C, Fourati S, Visseaux B, Soulié C, Wirden M, Katlama C, Yeni P, Brun-Vézinet F, Calvez V, Marcelin AG, Descamps D.

Antimicrob Agents Chemother. 2011 Apr;55(4):1754-7. doi: 10.1128/AAC.01049-10. Epub 2011 Jan 31.

44.

Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).

Gallien S, Journot V, Rozenbaum W, Yéni P, Morlat P, Poizot-Martin I, Reynes J, Reliquet V, Leclercq P, Simon F, Chêne G, Molina JM; ALIZE (ANRS 099) Study Group.

J Antimicrob Chemother. 2011 Jan;66(1):184-91. doi: 10.1093/jac/dkq395. Epub 2010 Oct 28.

PMID:
21036772
45.

Enfuvirtide: from basic investigations to current clinical use.

Joly V, Jidar K, Tatay M, Yeni P.

Expert Opin Pharmacother. 2010 Nov;11(16):2701-13. doi: 10.1517/14656566.2010.522178. Review.

PMID:
20977403
46.

Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.

Yeni P, Mills A, Peeters M, Vingerhoets J, Kakuda TN, De Smedt G, Woodfall B.

Curr HIV Res. 2010 Oct;8(7):564-76. Review.

PMID:
20946097
47.

Undetectable HIV-1 RNA load with the Cobas TaqMan v1.0 in a patient diagnosed at the time of primary HIV-1 infection.

Ghosn J, Galimand J, Meyer L, Descamps D, Vabret A, Deveau C, Yéni P, Goujard C, Rouzioux C, Chaix ML; French ANRS CO06 PRIMO Cohort.

J Med Virol. 2010 Nov;82(11):1816-8. doi: 10.1002/jmv.21827.

PMID:
20872706
48.

Deleterious pharmacokinetic interaction between bexarotene and efavirenz.

Desnoyer A, Kaied FA, Descamps D, Yeni P, Descamps V, Le Beller C, Peytavin G.

AIDS. 2010 Sep 10;24(14):2296-8. doi: 10.1097/QAD.0b013e32833d1243. No abstract available.

PMID:
20736686
49.

Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.

Delaugerre C, Charreau I, Braun J, Néré ML, de Castro N, Yeni P, Ghosn J, Aboulker JP, Molina JM, Simon F; ANRS 138 study group.

AIDS. 2010 Sep 24;24(15):2391-5. doi: 10.1097/QAD.0b013e32833d214c.

PMID:
20683319
50.

[Evaluation of initial antibiotic therapy for bacteremia and role of an antibiotic management team for antibiotic stewardship].

Diamantis S, Rioux C, Bonnal C, Papy E, Farfour É, Andremont A, Yeni P, Bouvet É, Lucet JC.

Med Mal Infect. 2010 Nov;40(11):637-43. doi: 10.1016/j.medmal.2010.06.002. Epub 2010 Jul 21. French.

PMID:
20650583

Supplemental Content

Support Center